Liu Chih-Yi, Chen Bo-Jung, Chuang Shih-Sung
Division of Pathology, Sijhih Cathay General Hospital, New Taipei City 221, Taiwan.
School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City 221, Taiwan.
Diagnostics (Basel). 2022 Mar 15;12(3):713. doi: 10.3390/diagnostics12030713.
Primary effusion lymphoma (PEL) is defined by the WHO classification as a large B-cell neoplasm without detectable tumor masses. It is universally associated with HHV8, with most cases occurring in the setting of immunodeficiency such as HIV infection, and a poor prognosis. Morphologically, the neoplastic cells range from immunoblastic, plasmablastic, to anaplastic; and phenotypically, most cases express plasma cell but not B-cell markers, i.e., plasmablastic. During the past decade, primary HHV8-negative effusion lymphoma has been reported. Such cases were considered in the WHO classification scheme as effusion-based lymphoma. We performed a systemic review of 167 HHV8-negative effusion lymphomas from the literature and found that only 42% were associated with a fluid overload state, and with low rates of HIV (6%) or EBV (21%) infection. Furthermore, most patients are old (or immunosenescent) with underlying medical conditions/comorbidities, most neoplasms are of B-cell phenotype, and the outcome is more favorable than that of HHV8-positive PEL. These distinctive findings supported our prior proposal of designating these HHV8-negative cases as type II PEL, in contrast to the classic or type I PEL as defined by the WHO. Furthermore, we propose an algorithmic approach for the diagnosis of PEL and its mimickers.
原发性渗出性淋巴瘤(PEL)被世界卫生组织分类定义为一种无法检测到肿瘤肿块的大B细胞肿瘤。它普遍与HHV8相关,大多数病例发生在免疫缺陷的情况下,如HIV感染,且预后较差。形态学上,肿瘤细胞范围从免疫母细胞、浆母细胞到间变性细胞;表型上,大多数病例表达浆细胞标志物而非B细胞标志物,即浆母细胞型。在过去十年中,已报道了原发性HHV8阴性渗出性淋巴瘤。此类病例在世界卫生组织分类方案中被视为基于渗出液的淋巴瘤。我们对文献中167例HHV8阴性渗出性淋巴瘤进行了系统综述,发现只有42%与液体超负荷状态相关,且HIV(6%)或EBV(21%)感染率较低。此外,大多数患者年龄较大(或存在免疫衰老)且有基础疾病/合并症,大多数肿瘤为B细胞表型,其预后比HHV8阳性的PEL更有利。这些独特的发现支持了我们之前提出的将这些HHV8阴性病例指定为II型PEL的提议,与世界卫生组织定义的经典或I型PEL形成对比。此外,我们提出了一种用于诊断PEL及其模仿者的算法方法。